Macter International Limited (PSX: MACTER) has successfully launched TirzaTrim (Tirzepatide), a next-generation treatment for Type 2 Diabetes Mellitus, in a multi-dose pre-filled pen presentation.
Read More: Atlas Honda 9MFY26 Profit Rises 43%, EPS at Rs122.73
TirzaTrim is a dual GIP (Glucose-Dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptor agonist. This medication not only aids in glycemic control but also offers additional benefits for weight reduction, representing a significant advancement in cardio-metabolic care.
The launch of the TirzaTrim Multidose Pre-Filled Pen marks a major milestone for the company, strengthening Macter’s position in advanced injectable drug delivery systems and complex biologics within the Pakistani market.
Macter International emphasized that this development reflects its continued commitment to introducing innovative, patient-centric therapies and expanding access to globally benchmarked treatments locally. The pre-filled pen delivery system is specifically designed to enhance patient convenience and compliance in long-term diabetes management.
